Photoactivation of lysosomally sequestered sunitinib after angiostatic treatment causes vascular occlusion and enhances tumor growth inhibition-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Photoactivation of lysosomally sequestered sunitinib after angiostatic treatment causes vascular occlusion and enhances tumor growth inhibition

Published:2015-02 Issue:2 Volume:6 Page:e1641-e1641
ISSN:2041-4889
Container-title:Cell Death & Disease
language:en
Short-container-title:Cell Death Dis

Author:

Nowak-Sliwinska P,Weiss A,van Beijnum J R,Wong T J,Kilarski W W,Szewczyk G,Verheul H M W,Sarna T,van den Bergh H,Griffioen A W

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Cell Biology,Cellular and Molecular Neuroscience,Immunology

Link

http://www.nature.com/articles/cddis20154.pdf

Reference37 articles.

1. Wood L . Sunitinib malate for the treatment of renal cell carcinoma. Exp Opin Pharmacother 2012; 13: 1323–1336.

2. Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006; 368: 1329–1338.

3. Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011; 364: 501–513.

4. Tannir NM, Plimack E, Ng C, Tamboli P, Bekele NB, Xiao L et al. A phase 2 trial of sunitinib in patients with advanced non-clear cell renal cell carcinoma. Eur Urol 2012; 62: 1013–1019.

5. Gan HK, Seruga B, Knox JJ . Sunitinib in solid tumors. Expert Opin Investig Drugs 2009; 18: 821–834.

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The tyrosine kinase inhibitor Nintedanib induces lysosomal dysfunctionality: role of protonation-dependent crystallization processes;Chemico-Biological Interactions;2024-09

2. Sunitinib malate induces cell death in adult human cardiac progenitor cells;Current Research in Toxicology;2024

3. Progress in the treatment of drug-loaded nanomaterials in renal cell carcinoma;Biomedicine & Pharmacotherapy;2023-11

4. Mechanisms of sunitinib resistance in renal cell carcinoma and associated opportunities for therapeutics;British Journal of Pharmacology;2023-10-19

5. Characterisation of tyrosine kinase inhibitor-receptor interactions at VEGFR2 using sunitinib-red and nanoBRET;Biochemical Pharmacology;2023-08

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3